“We are very pleased to have Dean join our board of directors,” said Brian K. Hutchison, RTI chairman and CEO. “In his 16 years at Stryker, he has played a key role in the financial growth of the company. With his experience in finance, accounting and tax processes, he will be a great asset to the RTI board.”

Bergy currently serves as advisor to the chief financial officer at Stryker, a position he has held since April 2009. He served the previous six years as Stryker’s vice president and chief financial officer. Prior to that, Bergy served as vice president of finance and chief accounting officer, vice president of finance for Stryker’s Medical Division, and started his tenure with Stryker in 1994 as the corporate controller. Previous to joining Stryker, he worked with Ernst & Young and Price Waterhouse. Bergy earned a bachelor’s degree in business administration from University of Michigan in Ann Arbor and completed the Program for Management Development from Harvard Business School.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and when possible, using proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s Web site at www.rtix.com or the SEC’s Web site at www.sec.gov.

###

RTI will hold a live conference call and simultaneous audio webcast on Wednesday, Aug. 4, 2010 at 9:00 a.m. ET to discuss second quarter results. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A telephone replay of the call will be available through Sept. 4, 2010 and can be accessed by calling (800) 642-1687, pass code 82510333; the replay will also be available at www.rtix.com.

About RTI Biologics Inc.

RTI Biologics Inc. is the leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and when possible, using proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s Web site at www.rtix.com or the SEC’s Web site at www.sec.gov.

###

• Robert P. Jordheim has joined the company as executive vice president and chief financial officer (CFO)
• Thomas F. Rose, executive vice president, has transitioned from the role of chief financial officer to RTI’s chief operations officer (COO)
• Caroline A. Hartill has been named executive vice president and chief scientific officer (CSO)
• Roger W. Rose has been named executive vice president and chief commercial officer (CCO)

All of these officers will report to Brian K. Hutchison, RTI chairman and chief executive officer, and together with him serve as the company’s Executive Management Committee. The Executive Management Committee oversees all aspects of the global company and develops and implements corporate strategy.

“These changes to our leadership team correspond with realignment in our organizational structure,” Hutchison said. “As we are moving through our initiative to improve operational and cost efficiencies while intensifying focus on customer service, we have grouped business and administrative departments under members of the Executive Management Committee. This team represents extensive leadership experience in medical devices, pharmaceuticals and tissue processing.”

Robert Jordheim, 46, joined the company on June 21, 2010 as executive vice president and CFO, and will oversee all aspects of finance for the company.

Jordheim has 24 years of progressive corporate finance experience, including 17 years with Medtronic, Inc. Most recently, he served as vice president, finance and business development for Medtronic’s Spinal and Biologics business unit. Previously, he served as vice president, finance for Medtronic’s Surgical Technologies business unit. His tenure with Medtronic also included responsibilities in corporate development and international experience gained through a five-year assignment in Europe. Previous to his tenure at Medtronic, Jordheim served as manager of external reporting at The Fairchild Corporation and an auditor for Deloitte & Touche.

Jordheim earned a bachelor’s degree in business administration from Southern Methodist University and a master’s degree in business administration from the University of Pittsburgh with a concentration in finance.

“We are very pleased to welcome Rob to the RTI team,” said Brian K. Hutchison, RTI’s chairman and CEO. “His extensive experience in the life science industry and skills in accounting and finance, business development and international business will be great assets to our company.”

Thomas Rose, 59, has transitioned from the role of executive vice president and CFO to the newly created position of executive vice president and COO. Rose assumed oversight responsibilities of operations in addition to finance and information technology in January 2010 as the company embarked on a global initiative to optimize operations. As COO, his responsibilities will include oversight of all aspects of the company’s global operations.

Rose joined RTI in May 2002 as vice president and CFO, and was promoted to executive vice president and CFO in February 2008. Before joining RTI, Rose served the previous 10 years as vice president and chief financial officer at A.M. Todd Group, based in Kalamazoo, Mich. He earned a bachelor’s degree in business administration from Western Michigan University in Kalamazoo. He has also completed numerous executive education courses at University of Michigan and Northwestern University focusing on strategy and organizational issues.

“Tom has been an asset to our leadership team since 2002,” Hutchison said “His knowledge of our business from Donor Services to distribution makes him the right leader to optimize our operations, making them as efficient and effective as we can while bringing customer service to its highest levels. This will be an intensive process that will be the foundation for our future growth, and with the addition of Rob to our team as CFO, Tom will be able to give this important initiative his full attention.”

Caroline Hartill, 53, has been named executive vice president and maintains her role as CSO, which was effective in March 2007. In her role, she oversees all quality assurance and regulatory affairs, as well as all research and development activities.

Hartill joined RTI in November 2001 and was named vice president of quality assurance and regulatory affairs in January 2003. For 18 years prior, she worked in the areas of technology development and market approvals as a freelance consultant working with many major and start-up biotechnology and medical device companies worldwide. Hartill earned a bachelor’s degree with honors in health sciences from Birmingham University Medical School in England, as well as a master’s degree in management from the University of Wolverhampton in England. Hartill has also earned master’s level credits in sterilization science from Manchester University.

Roger Rose, 51, will serve in the newly created position of executive vice president and CCO, with responsibilities for all marketing and distribution activities. He will continue to serve as president of RTI Donor Services, which was effective in February 2008. Within these two roles, Rose is committed to ensuring a meaningful connection between the donation and transplantation communities.

Rose joined RTI as vice president of donor services in October 2002 and assumed additional responsibility for distribution and marketing in October 2003. Prior to this, Rose spent seven years at Stryker Corporation based in Kalamazoo, Mich., where he held leadership positions in sales and marketing in both the medical and orthopedic divisions. Rose earned a bachelor’s degree in business administration from Western Michigan University in Kalamazoo and completed numerous executive education courses at UCLA, University of Michigan and Harvard Business School, focusing on finance, leadership, medical marketing, negotiation and strategy.

About RTI Biologics Inc.

RTI Biologics Inc. was formed when Regeneration Technologies Inc. and Tutogen Medical Inc. merged on Feb. 27, 2008. The company is now a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and when possible, using proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited by the American Association of Tissue Banks in the United States.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s Web site at www.rtix.com or the SEC’s Web site at www.sec.gov.

Quarterly Overview:

• Achieved revenues of $37.8 million and net loss of $54,000, or break even per fully diluted share
• Revenue impacted by $4.0 million inventory reduction by largest spine distributor
• Grew surgical specialties revenues 28 percent over first quarter 2009
• Launched one spinal implant, as well as three implants for bone graft substitutes and general orthopedics with three different distributors
• Launched the next-generation BTB Select®, which allows for precision sized matching relative to the intra-articular length of BTB allografts
• Reaffirms 2010 revenues guidance of $174.5 million to $177.5 million, and $0.15 to $0.17 cents per fully diluted share

Revenues were $37.8 million for the first quarter of 2010, compared to revenues of $38.6 million for the first quarter of 2009. For the first quarter of 2010, the company reported net loss of $54,000, or break even per fully diluted share based on 54.6 million fully diluted shares outstanding, compared to net income of $1.0 million and net income per fully diluted share of $0.02 based on 54.5 million fully diluted shares outstanding for the first quarter of 2009.

“Our results were significantly impacted by inventory reductions by our largest spine distributor and lower orders in the European markets,” said Brian K. Hutchison, chairman and CEO of RTI. “Despite the reduced revenue, we controlled expenses and generated positive operating cash flow during the quarter.”

First Quarter 2010 Analysis

Domestic revenues were $33.0 million for the first quarter of 2010, representing an increase of 2 percent over the prior year period. For the first quarter 2010, the strongest domestic performance was in surgical specialties and sports medicine, with year over year growth rates of 37 percent and 20 percent, respectively. In addition, domestic dental revenues grew 2 percent, and bone graft substitutes revenues grew 11 percent compared to the prior year period. Spine revenues, which declined by 33 percent, were negatively impacted by an inventory reduction of approximately $4 million from our largest distributor.

International revenues, which include exports and distribution from our German and French facilities, were $4.8 million for the first quarter of 2010, representing a decrease of 24 percent compared to the prior year period. Decreases in revenues were directly related to economic difficulties in several European countries, which impacted orders. Foreign currency translation adjustments resulted in an increase in first quarter revenues of $248,000 compared to the prior year period.

2010 Outlook

The company has provided guidance that 2010 revenues are estimated to grow between 6 percent and 8 percent, to between $174.5 million and $177.5 million. Full year earnings per fully diluted share are expected to be in the range of $0.15 to $0.17, based on 55.7 million fully diluted shares outstanding. There are no changes to this guidance at this time.

“We are confident that we will meet our financial expectations for the full year,” Hutchison said. “Our annual guidance reflected the inventory reductions by our largest spine distributor. We expect revenues to increase sequentially in the upcoming quarters due to new product launches, business development opportunities and stronger orders from each of our distributors.”

Conference Call

RTI will hold a live conference call and simultaneous audio Web cast on Wednesday, April 28, 2010 at 9:00 a.m. ET to discuss first quarter results. The conference call can be accessed by dialing (877) 383-7419. The Web cast can be accessed through the investor section of RTI’s Web site at www.rtix.com. A telephone replay of the call will be available through May 28, 2010 and can be accessed by calling (800) 642-1687, pass code 69679214; the replay will also be available at www.rtix.com.

About RTI Biologics Inc.

RTI Biologics Inc. was formed when Regeneration Technologies Inc. and Tutogen Medical Inc. merged on Feb. 27, 2008. The company is now a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and when possible, using proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited by the American Association of Tissue Banks in the United States.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s Web site at www.rtix.com or the SEC’s Web site at www.sec.gov.

RTI will hold a live conference call and simultaneous audio Web cast on Wednesday, April 28, 2010 at 9:00 a.m. ET to discuss first quarter results. The conference call can be accessed by dialing (877) 383-7419. The Web cast can be accessed through the investor section of RTI’s Web site at http://www.rtix.com. A telephone replay of the call will be available through May 28, 2010 and can be accessed by calling (800) 642-1687, pass code 69679214; the replay will also be available at http://www.rtix.com.

About RTI Biologics Inc
RTI Biologics Inc. is a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to penetrate tissue, inactivate or remove viruses and a wide range of organisms using worst-case testing and maintain tissue biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited in the U.S. by the American Association of Tissue Banks.

Forward Looking Statement
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s Web site at http://www.rtix.com or the SEC’s Web site at http://www.sec.gov.

###

“The launch of the hotline with RPI, a pre-eminent expert in the field of reimbursement, demonstrates RTI’s commitment to supporting our customers’ needs and provides a service that is very important given the complex reimbursement guidelines that exist today,” said Roger W. Rose, executive vice president for RTI.

The reimbursement hotline, staffed by qualified reimbursement specialists, can provide guidance to questions such as:

• How should this procedure be coded?
• How do we preauthorize this procedure with private payers?
• Does Medicare require preauthorization?
• What do we do in the event of claims denial and/or low payment?
• What sort of documentation should be submitted with our claim?

While RTI cannot instruct surgeons on coding procedures and reimbursement, its representatives can provide product information to assist the facility in coding correctly and, where required, obtaining the appropriate approvals. In addition, RTI engaged RPI to develop a reimbursement guide, which is now complete and available to customers as a guide for coding procedures and services involving its sports medicine line of implants.

RPI is an independent contractor and is not an affiliate, agent or joint venturer of RTI Biologics. For more information, contact your local RTI Biologics representative or call (386) 418-8888.

About RTI Biologics Inc
RTI Biologics Inc. is a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to penetrate tissue, inactivate or remove viruses and a wide range of organisms using worst-case testing and maintain tissue biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited in the U.S. by the American Association of Tissue Banks.

Forward Looking Statement
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s Web site at http://www.rtix.com or the SEC’s Web site at http://www.sec.gov.

###

BTB Select®
The next-generation BTB Select is an innovative solution that allows for precision sized matching relative to the intra-articular length of BTB allografts. The BTB Select is sterilized through RTI’s BioCleanse® process, which inactivates or removes potential pathogens from tissue using a specific formula while maintaining the tissue’s biomechanical properties.

“The BTB Select is an exciting allograft solution that addresses an overall market shift toward shorter BTBs, which are more difficult to recover naturally,” said Roger Rose, executive vice president for RTI Biologics. “This innovative product addresses a significant clinical need and ensures that we maximize every gift of donation received.”

Precision sized BTB intra-articular length is accomplished by utilizing an assembled cortical bone block in conjunction with an Achilles tendon, both derived from a single donor. The assembled cortical block features a proprietary anti-slip design, and the natural bone block allows for multiple fixation types.

“This new generation of assembled products provides significant processing advantages over previous designs and allows for reproducible machining and assembly,” Rose said. “These were two challenges faced in earlier designs, and we are pleased with the advancements made that enable us to produce a BTB allograft solution that meets our high quality and safety standards.”

BioCAP Select™
The BioCAP Select serves to broaden the sports medicine portfolio and marks RTI’s entry into the specialized area of Osteochondral Autograft Transfer System (OATS), a common procedure to treat small cartilage lesions.

The BioCAP Select is an innovative, fully biological bone void filler, and for the surgeon, this allograft provides a reliable solution to address voids created by OATS, which may lead to pain and/or discomfort for the patient if left empty.

RTI’s products are sterilized through processes validated by tissue type. The BioCAP Select implant is an assembled graft, derived from a single donor; the demineralized cortical cap is sterilized through the Cancelle™ SP DBM Sterilization Process, and the cancellous plug is sterilized through the BioCleanse® Tissue Sterilization Process.

The BTB Select is commercially available, while the BioCAP Select will be available through a limited launch following the AAOS meeting. Information and representative models for both BioCAP Select and BTB Select will be available at the AAOS meeting, booth #2967. For further information, contact an RTI representative at (800) 624-7238.

About RTI Biologics Inc
RTI Biologics Inc. is a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to penetrate tissue, inactivate or remove viruses and a wide range of organisms using worst-case testing and maintain tissue biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited in the U.S. by the American Association of Tissue Banks.

Forward Looking Statement
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s Web site at http://www.rtix.com or the SEC’s Web site at www.sec.gov.

###

ROSEMONT, IL – Dr. Robert C. Bray of the University of Calgary was recently selected as the winner of the American Orthopaedic Society for Sports Medicine’s (AOSSM) $250,000 Ligament and Tendon Repair and Regeneration Grant for his project, “Biological Augmentation of Ligament and Tendon Healing: Role of Neuropeptides.”

Dr. Bray and his colleagues (Paul Salo, University of Calgary, and Per Renstrom and Paul Ackermann, both with the Karolinska Institutet) will conduct a series of experiments designed first to define the cellular, physiological, mechanical and structural changes in healing chronically injured tendons and ligaments and then assess the impact of blocking the action of a specific inflammatory neuropeptide, or augmenting the action of an anti-inflammatory neuropeptide.

“We are grateful to AOSSM and RTI Biologics for selecting our project and allowing us to continue to study such an important piece of the ligament and tendon repair puzzle,” said Bray.

In 2006, the Society launched the first of a series of three-year research initiatives intended to highlight important issues in orthopaedic sports medicine and to promote high-level research in the selected topics. The first initiative focused on articular cartilage followed by the current initiative on ligament and tendon repair and regeneration. Following a think tank meeting in January 2009, and a grant workshop in July 2009, the Society solicited formal grant applications from workshop participants. This research initiative is sponsored by RTI Biologics Inc.

“We are proud to provide financial support to AOSSM’s research initiatives. The efforts of the AOSSM membership in the field of ligament and tendon repair and regeneration will lead to improved patient care. Continued research in this field is central to both the mission of RTI Biologics and the ongoing scientific leadership of the AOSSM,” said Rod Allen, Vice President of Sports Medicine Distribution, RTI Biologics Inc.

For more information on future AOSSM research initiatives, please visit http://www.sportsmed.org and click on the “research” tab.

###

The American Orthopaedic Society for Sports Medicine (AOSSM) is a world leader in sports medicine education, research, communication and fellowship, and includes national and international orthopaedic sports medicine leaders. The Society works closely with many other sports medicine specialists, including athletic trainers, physical therapists, family physicians, and others to improve the identification, prevention, treatment, and rehabilitation of sports injuries. For more information, please contact AOSSM Director of Communications, Lisa Weisenberger, at 847/292-4900. Additional information and press releases can be viewed in the newsroom on AOSSM’s Web site at http://www.sportsmed.org. For more information about RTI Biologics Inc. visit their Web site at http://www.rtix.com .

A group of surgeons from Barry University and Mercy Hospital in Miami, Fla., will leave this week to treat patients in Haiti, many of whom will need the Matrix HD™ allografts to save their arms or legs from amputation.

“These grafts from RTI are very important because we do not have the surgical equipment or facilities available to harvest autografts from the patients, and we can apply these allografts without general anesthesia,” said Dr. Thomas J. Merrill, D.P.M., professor of surgery for the School of Podiatric Medicine at Barry University and podiatric reconstructive surgeon for Mercy Hospital. “The Matrix HD allografts are durable and will withstand the conditions in Haiti right now. These grafts will save these patients’ limbs.”

Matrix HD is acellular human dermis processed using the Tutoplast® Tissue Sterilization Process. The allograft dermis is collagenous connective tissue with three-dimensional intertwined fibers that retain the multidirectional and mechanical properties of native dermis. Matrix HD supports cellular revascularization and repopulation by the host tissue and has been used in a variety of applications, including sports medicine, urology, breast reconstruction and other surgical specialties.

“RTI is pleased to donate Matrix HD to treat these patients,” said Roger W. Rose, executive vice president for RTI. “We commend and support our surgeon customers in their contributions to this much needed cause and their efforts to use Matrix HD to help people affected by the earthquake in Haiti.”

Allograft is tissue surgically transplanted from one person to another. Most allograft tissue is recovered surgically after someone dies; the donor must have consented to the donation before death or the donor’s family must consent after death. Tissue transplantation can have many benefits for recipients including repairing tissue defects caused by trauma or disease, restoring mobility and regaining independence in daily activities.

Allografts are used as an alternative to synthetic and metal implants. However, unlike synthetic or metal implants, allografts are a natural and biocompatible scaffold, allowing the recipient’s body to remodel it into his or her own tissue over time. Using allograft tissue rather than an autograft – or tissue from one’s own body – eliminates a second surgical site, allowing the recipient to avoid additional pain, risk and a possible longer hospital stay.

RTI honors the gift of tissue donation by treating the tissue with respect, by finding new ways to use the tissue to help patients and by helping as many patients as possible from each donation.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to penetrate tissue, inactivate or remove viruses and a wide range of organisms using worst-case testing and maintain tissue biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited in the U.S. by the American Association of Tissue Banks.

###

Quarterly Highlights:

• Revenues of $42.0 million, an increase of 12 percent over the prior year period
• Net income of $1.5 million, or $0.03 per fully diluted share
• Surgical specialties revenues increased 86 percent compared to the prior year period
• Sports medicine revenues increased 9 percent sequentially and 22 percent compared to the prior year period
• Launched three implants in orthopedics and bone graft substitutes for three different distributors

2009 Full Year Highlights:

• Record revenues of $164.5 million, an increase of 12 percent over the prior year period
• Net income of $5.9 million, or $0.11 per fully diluted share
• Closed $11.75 million financing agreement with Mercantile Bank on Jan. 28, 2009
• Increased number of direct biologic representatives to a total of 36, compared to 30 at the beginning of the year
• Amended agreement for exclusive worldwide distribution rights for dermal allografts for use in hernia repair with Davol Inc., a subsidiary of C.R.Bard Inc., to include dermal allografts for breast reconstruction
• Signed a new agreement to provide spinal allograft implants to Aesculap Implant Systems, Inc.
• Launched 13 new implants and two line extensions in the spine and orthopedics markets, which accounted for over $6 million of revenue for the year
• Launched five new implants, including bovine pericardium line and initial dermis implant with ENTrigue for use in the otolaryngology market, and three line extensions in surgical specialties
• Introduced two new sports medicine implants – Matrix HD™, which surpassed $1 million in revenue for the year, and Fresh OC Talus, an extension of the fresh osteochondral line, which increased by 98 percent in revenues compared to the previous year

Revenues were $42.0 million for the fourth quarter of 2009, representing a 12 percent increase compared to revenues of $37.4 million for the fourth quarter of 2008. Revenues for the full year 2009 were $164.5 million, representing a 12 percent increase compared to revenues of $146.6 million for 2008. The increase in year over year revenues reflects the inclusion of Tutogen Medical for the full 12 months of 2009 compared to the period of Feb. 28 to Dec. 31, 2008 in the prior year. Tutogen Medical revenues for the period Jan. 1, 2008 to Feb. 27, 2008 were $8.5 million, including international revenues of $3.0 million.

For the fourth quarter of 2009, the company reported net income of $1.5 million and net income per fully diluted share of $0.03 based on 54.9 million fully diluted shares outstanding, compared to net loss of $102.5 million and net loss per fully diluted share of $1.89 based on 54.1 million fully diluted shares outstanding for the fourth quarter of 2008. The net loss in the fourth quarter of 2008 reflected asset impairments and abandonments of $104.4 million, or a $1.92 decrease per fully diluted share.

For the full year 2009, the company reported net income of $5.9 million and net income per fully diluted share of $0.11 based on 54.8 million fully diluted shares outstanding, compared to net loss of $100.0 million and net loss per fully diluted share of $2.00 based on 49.9 million fully diluted shares outstanding for 2008.

“In a very challenging and difficult-to-predict environment, we were able to increase our revenues by 12 percent,” said Brian K. Hutchison, chairman and CEO of RTI. “Our sports medicine and surgical specialties businesses have been the fastest-growing businesses over the year, offsetting a decline in dental business. We worked very diligently over the past 12 months to leverage our operational strengths and make steady improvements in our profitability while meeting the needs of our surgeons and distributors. These improvements should help us with our goals of delivering significant gains in profitability in 2010.”

Revenue Analysis

Domestic revenues were $35.9 million for the fourth quarter and $141.3 million for the full year 2009, representing increases of 9 percent and 11 percent respectively over prior year results for each period. The increase in revenues for the full year reflects the inclusion of Tutogen revenues for 12 months in 2009 versus the period of Feb. 28 to Dec. 31, 2008 in the prior year. For the fourth quarter and full year 2009, the strongest domestic performance was in surgical specialties, with year over year growth rates that exceeded market growth rates due to increased sourcing of membrane tissue to support these markets. Sports medicine revenues also grew year over year and reached record levels in the fourth quarter. Growth in sports medicine and surgical specialties offset a decline in dental revenues for the year, which have been significantly impacted by the global economic slowdown.

International revenues, which include exports and distribution from the company’s German and French operations, were $6.1 million for the fourth quarter of 2009 and $23.3 million for the full year 2009, representing increases of 37 percent and 18 percent respectively, compared to the prior year periods. Export revenues increased by $640,000 in the fourth quarter and $1.0 million for the year compared to the prior year periods. Foreign currency translation adjustments resulted in an increase in fourth quarter revenues of $542,000 and a decrease in full year 2009 revenues of $917,000 compared to prior year periods. In addition, full year revenues reflect the inclusion of Tutogen Medical revenues for the full 12 months in 2009 versus the period of Feb. 28 to Dec. 31, 2008 in the prior year.

2010 Outlook

The company expects full year revenues for 2010 to increase between 5 percent and 7 percent on a constant currency basis. Assuming foreign currency exchange rates remain near year-end 2009 levels, the company estimates that foreign currency translation adjustments will increase revenues by approximately 1 percent for the full year 2010, resulting in reported revenue growth between 6 percent and 8 percent, or between $174.5 million and $177.5 million. Full year earnings per fully diluted share are expected to be in the range of $0.15 to $0.17, based on 55.7 million fully diluted shares outstanding.

“Our management team feels that through double digit growth in sports medicine and surgical specialties, combined with new product launches in all areas of our business through the year, we will be able to meet the outlook we have set for 2010,” Hutchison said. “With unknowns surrounding health care reform and the global economy, our management team understands that growth will be challenging, but we are committed to achieving our goals, growing our revenues and earnings over the long term while focusing on improving profitability and cash flow.”

Conference Call

RTI will hold a live conference call and simultaneous audio Web cast on Tuesday, Feb. 9, 2010 at 9:00 a.m. ET to discuss the 2009 fourth quarter and year end results, as well as guidance for 2010. The conference call can be accessed by dialing (888) 500-6974. The Web cast can be accessed through the investor section of RTI’s Web site at www.rtix.com. A telephone replay of the call will be available through March 1, 2010 and can be accessed by calling (888) 203-1112, passcode 6416137; the replay will also be available at www.rtix.com.

About RTI Biologics Inc.

RTI Biologics Inc. was formed when Regeneration Technologies Inc. and Tutogen Medical Inc. merged on Feb. 27, 2008. The company is now a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and when possible, using proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited by the American Association of Tissue Banks in the United States.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s Web site at www.rtix.com or the SEC’s Web site at www.sec.gov.

ALACHUA, Fla. (Jan. 28, 2010) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), the Florida-based processor of orthopedic, dental, hernia and other biologic implants, has donated a sterilized dermis allograft, Matrix HD™, to treat an eight-year old patient with a rare skin disease called recessive dystrophic epidermolysis bullosa (EB).

This is the first time terminally sterilized allograft dermis will be used to treat this disease. The patient is being treated at the Children’s Hospital of Denver, one of only five centers in the United States that have a multidisciplinary EB center.

“We are extremely grateful for this generous donation from RTI,” said Alan Arbuckle, MD, director of the Wound Care Clinic and co-director of the EB Center of Excellence at the Children’s Hospital of Denver. “Patients with recessive dystrophic EB do not make type VII collagen. Matrix HD lays down the collagen scaffolding so that the skin cells can migrate and help heal the wounds.”

EB is an inherited, blistering skin condition that varies widely in severity and forms. Patients with this disease lack anchors that hold the layers of their skin together, so any activity that rubs or causes pressure produces a painful sore or formation of fluid-filled blisters similar to a second-degree burn. Regular protection of the skin with gauze and ointments is necessary to prevent and protect the wounds and healthy skin. Currently, there is no cure for the disease that affects more than 10,000 children and adults in the United States. Approximately 600 people suffer from the recessive dystrophic form of the disease.

“EB is a disease that has multiple complications, including chronic pain. The grafting with Matrix HD is used to heal wounds so the patient experiences less pain in her lifetime.” Arbuckle said. “We will patchwork the grafts across her back every two months until the area is healed. So far, we have noticed that a large chronic wound on her back has started to heal. It is important to note, however, that because EB does not currently have a cure, the affected areas likely will need to be treated again in the future.”

Matrix HD is acellular human dermis processed using the Tutoplast® Tissue Sterilization Process. The allograft dermis is collagenous connective tissue with three-dimensional intertwined fibers that retain the multidirectional and mechanical properties of native dermis. Matrix HD supports cellular revascularization and repopulation by the host tissue and has been used in a variety of applications, including sports medicine, urology, breast reconstruction and other surgical specialties.

“RTI is pleased to donate Matrix HD to treat this patient,” said Roger Rose, executive vice president for RTI. “The Children’s Hospital of Denver is touted for excellence with its inpatient and outpatient wound program, and we applaud their efforts to use Matrix HD to help this little girl’s severe pain and give her some comfort.”

Allograft is tissue surgically transplanted from one person to another. Most allograft tissue is recovered surgically after someone dies; the donor must have consented to the donation before death or the donor’s family must consent after death. Tissue transplantation can have many benefits for recipients including repairing tissue defects caused by trauma or disease, restoring mobility and regaining independence in daily activities.

RTI honors the gift of tissue donation by treating the tissue with respect, by finding new ways to use the tissue to help patients and by helping as many patients as possible from each donation.

About the Children’s Hospital of Denver

The Children’s Hospital is a leading pediatric health-care network dedicated 100 percent to caring for kids. It continues to be designated one of the nation’s outstanding children’s hospitals by U.S. News & World Report and Child Magazine. With more than 1000 experienced experts representing the full spectrum of pediatric specialties, Children’s is home to many nationally and internationally recognized medical and research programs. Children’s provides complete pediatric care at its main campus and through a network of care that includes ten Children’s Care Centers and more than 400 outreach clinics. For more information, visit us at www.thechildrenshospital.org

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to penetrate tissue, inactivate or remove viruses and a wide range of organisms using worst-case testing and maintain tissue biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited in the U.S. by the American Association of Tissue Banks.

###

ALACHUA, Fla. (Jan. 20, 2010) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), the Florida-based processor of orthopedic, dental, hernia and other biologic implants, will be releasing financial results from the 2009 fourth quarter and year end on Tuesday, Feb. 9, 2010 before the market opens. The company will also outline financial guidance for the full year 2010.

RTI will hold a live conference call and simultaneous audio Web cast on Tuesday, Feb. 9, 2010 at 9:00 a.m. ET to discuss the 2009 fourth quarter and year end results, as well as guidance for 2010. The conference call can be accessed by dialing (888) 500-6974. The Web cast can be accessed through the investor section of RTI’s Web site at www.rtix.com. A telephone replay of the call will be available through March 1, 2010 and can be accessed by calling (888) 203-1112, passcode 6416137; the replay will also be available at www.rtix.com.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to penetrate tissue, inactivate or remove viruses and a wide range of organisms using worst-case testing and maintain tissue biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited in the U.S. by the American Association of Tissue Banks.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the Securities and Exchange Commissions (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s Web site at www.rtix.com or the SEC’s Web site at www.sec.gov.

###

Blakely has joined RTI as vice president of sports medicine marketing. Her role is to oversee all aspects of the company’s sports medicine marketing, including developing strategic plans for the franchise and directing the priorities of product development. Prior to joining RTI, Blakely spent more than five years at Zimmer Inc., including serving as director of relationship management and surgeon communications, director of U.S. regional marketing for hips and director of global marketing for hips. Previous to her time at Zimmer, Blakely oversaw the hip portfolio at Exactech Inc. Her experience also includes sales and product management at Smith & Nephew. Blakely earned a bachelor’s degree in business administration with a concentration in sales and marketing and a master’s degree in business administration, both from the University of Memphis in Tennessee.

“Christie’s experience in marketing, product development and surgeon relationships will be very valuable to our sports medicine franchise,” said Brian K. Hutchison, chairman and CEO of RTI. “We are committed to growing our sports medicine business to be the largest segment in the company, and we are investing resources accordingly. With Christie’s focus on the marketing and product development side of the sports medicine business, Rod Allen, our vice president of sports medicine distribution can focus on our expanding direct distribution force and getting our best-in-class biologic portfolio to the surgeons that need them.”

LaPrade joined RTI as vice president of surgical specialties, overseeing business and product development for one for the fastest growing areas of the company. LaPrade has more than 16 years experience in sales and marketing for pharmaceutical, medical equipment and medical device companies such as TYCO Healthcare, Boston Scientific and most recently, Gambro Renal Products. Prior to joining RTI, LaPrade served more than two years as vice president of Americas marketing for Gambro’s intensive care division. He earned a bachelor’s degree in business administration with a concentration in marketing at Bryant University in Rhode Island.

“Mike’s expertise in assessing competitive markets and new business opportunities, as well as managing product development, will be key for our fast-growing surgical specialties business,” Hutchison said. “There are many opportunities for us to provide sterile biologic solutions for surgeons and their patients with our surgical specialties portfolio. Mike and his team will be focused on seeking out those opportunities and continuing to foster the growth of this business.”

About RTI Biologics Inc.

RTI Biologics Inc. is the leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited by the American Association of Tissue Banks in the United States.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the Securities and Exchange Commissions (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s Web site at www.rtix.com or the SEC’s Web site at www.sec.gov.

###

The allograft implants will be used for spinal fusions to treat congenital spinal deformities, limb defects and vertebral reconstruction for tuberculosis infection in Kenyan children. Without surgical reconstruction, spines affected by tuberculosis often collapse and paralyze those affected. In addition, limb defects and impediments make life difficult and limit opportunities for these children to grow and reach their full potential.

“This donation has allowed us to reach new heights of surgical reconstruction in Kenya,” said Timothy C. Mead, MD, medical director of CURE Kenya. “Without RTI’s support, our potential would not be as great and fewer children would have their lives transformed through successful surgery.”

AIC-CURE International Children’s Hospital has provided life-changing surgeries to more than 22,000 Kenyan children since 1998.

“Our mission at RTI is to improve lives through biologic solutions to achieve life-restoring and life-saving results,” said Brian K. Hutchison, chairman and CEO for RTI. “Through the generous gift of tissue donation, RTI is able to provide these allografts to children in need.”

Allograft is tissue surgically transplanted from one person to another. Most allograft tissue is recovered surgically after someone dies; the donor must have consented to the donation before death or the donor’s family must consent after death. Tissue transplantation can have many benefits for recipients including repairing tissue defects caused by trauma or disease, restoring mobility and regaining independence in daily activities.

Allografts are used as an alternative to synthetic and metal implants. However, unlike synthetic or metal implants, allografts are a natural and biocompatible scaffold, allowing the recipient’s body to remodel it into his or her own tissue over time. Using allograft tissue rather than an autograft – or tissue from one’s own body – eliminates a second surgical site, allowing the recipient to avoid additional pain, risk and a possible longer hospital stay.

RTI honors the gift of tissue donation by treating the tissue with respect, by finding new ways to use the tissue to help patients and by helping as many patients as possible from each donation.

About CURE International

Founded in 1996, CURE International is the largest provider of pediatric specialty surgical care in the developing world, transforming the lives of children with physical disabilities and their families through medical and spiritual healing. A nonprofit medical organization, CURE International specializes in the treatment of children with curable orthopedic and neurosurgical conditions. It also provides medical education and training programs to national medical professionals throughout the developing world. To date, it has performed more 70,000 surgeries and seen more than one million patients. Visit www.cureinternational.org for more information.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to penetrate tissue, inactivate or remove viruses and a wide range of organisms using worst-case testing and maintain tissue biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited in the U.S. by the American Association of Tissue Banks.

Tim Heffernan, son of Linda Heffernan, will ride the Donate Life float in recognition of the thousands of people who donate tissue each year. Tim’s trip to Pasadena is sponsored by RTI Donor Services, which is one of more than 50 associations across the nation — including recovery organizations, industry partners, transplant centers and transplant recipient groups — supporting the float project. Tim is an employee of RTI Biologics, the Alachua-based organization that prepared his mother’s donated tissue, which resulted in the preparation of more than 20 implants, which have been or will be used in a variety of medical procedures to help others.

Linda Heffernan, a native of Melbourne, Fla., passed away suddenly at the age of 50 in February 1999 from a pulmonary embolism, five days after undergoing elective surgery. According to her family, she was a daughter, sister, wife, mother, aunt, grandmother and a friend. She raised three children – Tim and two older sisters, Karen and Kim.

As many donor families know, when a close family member passes away, emotions are high and it’s during this time that a family is challenged to make tough decisions. One of those decisions is that of organ and tissue donation. Tim testifies, “It’s not really something you want to think about, but it’s a decision that needs to be made. In regard to my mother, it was an easy decision for our family to make. Actually, it was a decision that had already been made by her long before she passed away.”

Tim said that he comes from a family that believes in organ and tissue donation. Donation had been a topic of discussion within his family on several occasions prior to his mother’s passing. During these discussions, Tim remembers his mother saying, “Let them have what they want; I don’t need it anymore.” So Linda’s family consented to donate her tissue with the hope that their decision would someday benefit other individuals.

The Donate Life Rose Parade float, one of 90 parade floats and units in this year’s “A Cut Above the Rest,” themed parade, will present the theme “New Life Rises” as it symbolizes the importance of donation. The float’s soaring phoenix, a symbol of life emerging from the ashes of death, displays a message of hope and inspiration, honoring those who make the gift of life an inspiring story of courage, compassion, and renewal.

Tim said he remembers his father showing him a letter he received from a company called Regeneration Technologies (now RTI Biologics), thanking the family for Linda’s donation. Tim said he never would have guessed that six years after her passing, he would come to work for the same company that received his mother’s donated tissue.

“In the end, my mother’s gift had a positive impact on other people’s lives due in large to the hard work of RTI employees. I personally have the privilege to work side-by-side with incredible people on a daily basis in all different departments, all of them working toward a common goal – to improve the quality of life for people, people they don’t even know,” Tim said. “I spoke to my family about what it is we do at RTI. I explained to them the different ways donated tissue is used to help others and how RTI takes great care to ensure that each donor’s tissue reaches as many individuals as possible.”

The 121st Rose Parade, “A Cut Above the Rest,” will take place at 8 a.m. Pacific Standard Time on Friday, Jan. 1, 2010. For more information on the “New Life Rises” float, visit the official Web site at www.donatelifefloat.org.

Today, more than 100,000 children and adults await life-saving organ transplants in the United States. More than 3,000 of them are in Florida. Hundreds of thousands more are in need of a tissue transplant to greatly enhance the quality of their lives. You can join Florida’s donor registry at any time by visiting www.donatelifeflorida.org and designate your wishes.

Donor Services is a not-for-profit tissue recovery network dedicated to serving donor families and the donation community in perpetuating the circle of life. In addition to offering families the option of tissue donation, RTI Donor Services supports their wishes as a responsible steward of human donated tissue gifts, and provides family services, as well as community information and awareness. RTI Donor Services is accredited in the United States by the American Association of Tissue Banks. For more information on RTI Donor Services, visit www.rtidonorservices.org.

RTI Donor Services is affiliated with RTI Biologics, a leading provider of sterile biological implants for surgeries around the world. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes.

These allograft and xenograft implants are used in spinal, sports medicine, orthopedic, dental and other specialty surgeries.

For more information on RTI Biologics, visit www.rtibiologics.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6121305&lang=en

“Being recognized by BioFlorida for the Gury Company of the Year Award is a wonderful honor for RTI,” said Brian K. Hutchison, chairman and CEO for RTI. “Since spinning out of the University of Florida many years ago, RTI has had the opportunity to achieve significant growth and to make a very real impact on biologics. We are committed to continued growth as the use of biologics in surgery becomes more and more prevalent. With the support of our legislators and the collaboration of the biotechnology industry, the state of Florida is growing as a knowledge economy, and we look forward to many more successes in this industry in the future.”

The Gury Company of the Year Award recognizes businesses for their contributions to upholding the legacy of one of the founding members and a past chairman of BioFlorida, David Gury. Gury has created and managed biotechnology companies that foster the industry’s growth and continue to serve as an advocate and leader in Florida’s bioscience community.

RTI was selected for the award by a panel of industry leaders.

About BioFlorida

BioFlorida is Florida’s statewide trade association for the bioscience industry providing advocacy, business development and communications services for more than 200 member companies. Our mission is to be the voice of the bioscience industry and the advocate for our member organizations. Bringing knowledge and resources to Florida’s bioscience community, BioFlorida supports the health, agricultural and energy sectors of biotechnology as well as the pharmaceutical and medical technology fields.

About RTI Biologics Inc.

RTI Biologics, Inc. is a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to penetrate tissue, inactivate or remove viruses and a wide range of organisms using worst-case testing and maintain tissue biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited in the U.S. by the American Association of Tissue Banks.

ALACHUA, Fla. (Oct. 28, 2009) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading processor of orthopedic and other biologic implants, reported operating results for the third quarter ended Sept. 30, 2009.

Quarterly Highlights:

• Record revenues of $42.8 million
• Net income of $2.3 million, or $0.04 per fully diluted share, compared to $388,000, or $0.01 per fully diluted share, as a result of continued increased revenues and margins
• Amended agreement for exclusive worldwide distribution rights for dermal allografts for use in hernia repair with Davol Inc., a subsidiary of C.R.Bard Inc., to include dermal allografts for breast reconstruction
• Record revenues in domestic hernia repair, an increase of more than 150 percent over the previous year’s period
• Increased breast reconstruction revenues by 66 percent over the prior year’s period, reflecting launch quantity shipments to Davol Inc.
• Launched four new orthopedic implants
• Received FDA clearance to market bovine pericardium for use in ENT procedures

Revenues were $42.8 million for the third quarter of 2009, representing an 11 percent increase compared to revenues of $38.5 million for the third quarter of 2008. Revenues were $122.6 million for the first nine months of 2009, representing a 12 percent increase compared to revenues of $109.3 million for the first nine months of 2008. The increase in year-over-year revenues for the first nine months reflects the inclusion of Tutogen Medical for the full nine months of 2009 compared to the period of Feb. 28 to Sept. 30, 2008 in the prior year. Tutogen revenues for the period Jan. 1, 2008 to Feb. 27, 2008 were $8.5 million, including international revenues of $3.0 million.

For the third quarter of 2009, the company reported net income of $2.3 million and net income per fully diluted share of $0.04 based on 55 million fully diluted shares outstanding, compared to net income of $388,000 and net income per fully diluted share of $0.01 for the third quarter of 2008, based on 55.7 million fully diluted shares outstanding. For the first nine months of 2009, the company reported net income of $4.4 million and net income per fully diluted share of $0.08 based on 54.7 million fully diluted shares outstanding, compared to net income of $2.5 million and net income per fully diluted share of $0.05 based on 50.4 million fully diluted shares outstanding for the same period last year.

“Our third quarter results were in line with our expectations,” said Brian K. Hutchison, RTI chairman and chief executive officer. “As we enter the last quarter of the year, we are mindful of the continued weakness in the global economy and its impact on procedure volumes and the orthopedic markets in general. Accordingly, we are working diligently to ensure we meet our goals for our distributors and our shareholders.”

Revenue Analysis

Domestic revenues were $37.4 million for the third quarter and $105.4 million for the first nine months of 2009, both representing increases of 12 percent over prior year results for each period. The increase in revenues for the first nine months reflects the inclusion of Tutogen revenues for nine months in 2009 versus the period of Feb. 28 to Sept. 30, 2008 in the prior year. For the third quarter and first nine months of 2009, the strongest domestic performance was in surgical specialties, with sequential and year-over-year growth rates that exceeded market growth rates as we continue to increase sourcing of membrane tissue to support these markets. Growth in surgical specialties offset a decline in dental revenues, which have been significantly impacted by the global economic slowdown. The sports medicine business continues to grow; however, the third quarter revenues were negatively impacted by both a seasonal slowdown in procedures and deferral of procedures due to global economic conditions.

International revenues, which include exports and distribution from our German and French operations, were $5.4 million for the third quarter of 2009 and $17.2 million for the first nine months of 2009, representing increases of 8 percent and 13 percent respectively compared to the prior year period. During the third quarter and first nine months of 2009, currency exchange fluctuations resulted in a decrease in revenues of $229,000 and $1.5 million respectively compared to prior year periods. In addition, first nine month revenues reflect the inclusion of Tutogen revenues for the full nine months in 2009 versus the period of Feb. 28 to Sept. 30, 2008 in the prior year.

2009 Outlook

The company’s 2009 financial guidance includes revenues estimated to be $166 to $168 million, with fully diluted earnings per share of $0.11 to $0.13. There are no changes to this guidance at this time.

Conference Call

RTI will hold a live conference call and simultaneous audio Web cast on Wednesday, Oct. 28, 2009 at 9:00 a.m. ET to discuss third quarter results. The conference call can be accessed by dialing (888) 452-4004. The Web cast can be accessed through the investor section of RTI’s Web site at www.rtix.com. A telephone replay of the call will be available through Nov. 18, 2009 and can be accessed by calling (888) 203-1112, passcode 7047465; the replay will also be available at www.rtix.com.

About RTI Biologics Inc.

RTI Biologics Inc. was formed when Regeneration Technologies Inc. and Tutogen Medical Inc. merged on Feb. 27, 2008. The company is a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and when possible, using proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited by the American Association of Tissue Banks in the United States.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates”, “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

RTI will hold a live conference call and simultaneous audio Web cast on Wednesday, Oct. 28, 2009 at 9:00 a.m. ET to discuss third quarter results. The conference call can be accessed by dialing(888) 452-4004. The Web cast can be accessed through the investor section of RTI’s Web site at http://www.rtix.com. A telephone replay of the call will be available through Nov. 18, 2009 and can be accessed by calling (888) 203-1112, passcode 7047465; the replay will also be available at http://www.rtix.com.

About RTI Biologics Inc.

RTI Biologics Inc. is the leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited by the American Association of Tissue Banks in the United States.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates”, “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the Securities and Exchange Commissions (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

RTI received the award for business expansion at an awards luncheon in Gainesville, Fla. and was among six local companies that received 2009 Business of the Year Awards. RTI was chosen for this award based on exceptional contributions toward local economic diversification through job creation and distinctive community involvement and investment.

“Being recognized in our local community for the 2009 Business Expansion Award is another important recognition for RTI,” said Brian K. Hutchison, chairman and CEO for RTI. “This award is a testament to the hard work of all of our employees and the management team that helped with the merger and integration of Regeneration Technologies, Inc. and Tutogen Medical, Inc., which resulted in the formation of RTI Biologics.”

The Gainesville Area Chamber of Commerce awarded businesses that have excelled in entrepreneurship, innovation, expansion and commitment to the environment.

The recipients were selected by an independent panel of judges from among past award recipients and local business people. The judges reviewed each of the nominated businesses’ applications and, using a standardized judging form, assigned points based on the companies’ achievements in separate criteria including recent expansion of the business, community involvement and charitable fundraising, among others.

About RTI Biologics Inc.

RTI Biologics, Inc. is the leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to penetrate tissue, inactivate or remove viruses and a wide range of organisms using worst-case testing and maintain tissue biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international facilities in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited in the U.S. by the American Association of Tissue Banks.

RTI received the award for business expansion in the major market category at an awards luncheon at the Florida Capitol in Tallahassee, Fla. and was among 20 Florida companies that received 2009 Governor’s Business Diversification Awards. RTI was chosen for this award based on exceptional contributions toward statewide economic diversification through job creation and distinctive community involvement and investment.

“This Governor’s Business Expansion Award is a wonderful recognition for RTI, and we are honored to be recognized at this level,” said Brian K. Hutchison, chairman and CEO for RTI. “This award further demonstrates our commitment to growth and recognizes continued success following the 2008 merger of Regeneration Technologies, Inc. and Tutogen Medical, Inc.”

The awards program is sponsored annually by Enterprise Florida, Inc. (EFI) in conjunction with Florida’s Industry Appreciation Week held Sept. 14-18, 2009, which promotes outstanding accomplishments made by the state’s businesses.

“These awards acknowledge the successes of a wide range of business leaders whose accomplishments have benefited our economy,” said Enterprise Florida President & CEO John Adams Jr. “Therefore, Industry Appreciation Week and the awards program celebrate their exemplary efforts and the attributes that brought them about: innovation, entrepreneurship, corporate leadership, and volunteerism.”

Companies vied in six categories: Business Expansion, Entrepreneurship, Export Excellence, Innovation, Newcomer and Green-to-Gold. Each nominee competed with other companies, organizations, universities and colleges in similarly sized markets, including Mid Market (county population up to 150,000); Major Market (county population 150,001 to 800,000) and Mega Market (county population 800,001 and higher).

Winners were chosen for demonstrating a commitment to creating jobs for Floridians, increasing capital investment and promoting corporate citizenship.

About Enterprise Florida

Enterprise Florida, Inc. (EFI) is a partnership between Florida’s business and government leaders and is the principal economic development organization for the state of Florida. Headquartered in Orlando, EFI’s mission is to diversify Florida’s economy and create better-paying jobs for its citizens by supporting, attracting and helping to create businesses in innovative, high-growth industries. In pursuit of its mission, EFI works closely with a statewide network of economic development partners and is funded both by the State of Florida and by private-sector businesses.

About RTI Biologics Inc.

RTI Biologics Inc. is the leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to penetrate tissue, inactivate or remove viruses and a wide range of organisms using worst-case testing and maintain tissue biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international facilities in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited in the U.S. by the American Association of Tissue Banks.